Clinical Takeaway
In this randomized, double-blind, placebo-controlled crossover trial in healthy adults, neither a low nor a high single dose of CBD produced measurable changes in cortical excitability or sedation compared to placebo. This suggests that CBD’s well-documented anti-seizure benefits in conditions like Dravet syndrome and Lennox-Gastaut syndrome may depend more on its interaction with clobazam than on any direct effect on brain excitability. Patients and clinicians should understand that CBD alone, outside the context of combination therapy, may not be acting on the brain in the ways commonly assumed.
#10 Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.
Citation: Gorbenko Andriy A et al.. Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.. Clinical pharmacology and therapeutics. 2026. PMID: 40836528.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This study clarifies that CBD’s clinical efficacy in seizure disorders may depend primarily on pharmacokinetic interactions with concomitant medications like clobazam rather than direct effects on neuronal excitability, fundamentally altering how clinicians should conceptualize its mechanism of action. Understanding CBD’s lack of direct cortical effects has important implications for patient selection, dosing strategies, and the rational design of combination antiseizure regimens, particularly in polypharmacy scenarios. These findings suggest that CBD’s therapeutic benefit in Dravet and Lennox-Gastaut syndromes cannot be extrapolated to seizure conditions treated without concurrent clobazam or similar drug interactions.
Abstract: Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with Dravet syndrome, Lennox-Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and adverse effects are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti-seizure medication (ASM). The goal of this study was to evaluate the intrinsic anti-epileptic and sedative properties of CBD. A randomized, double-blind, placebo-controlled, 3-way crossover trial was conducted in 25 healthy males. On each visit, single doses of 30 mg CBD, 700 mg CBD, or placebo were administered orally. The effects of CBD on cortical excitability were measured using transcranial magnetic stimulation (TMS) combined with electromyography (EMG) and electroencephalography (EEG). Sedative properties were assessed using a validated CNS test battery. Pharmacokinetic sampling was performed. Data were analyzed using a mixed-effects model. CBD did not have significant effects on single pulse and paired pulse TMS-EMG parameters, compared to placebo. Some significant clusters were seen on paired pulse TMS-EEG at 3 hours post-dose for 30 mg CBD, and at 3 and 5 hours post-dose for 700 mg CBD. CBD did not have significant effects on any tests assessing its sedative properties. These results suggest that CBD may lack intrinsic anti-epileptic and sedative properties and that its effects could be primarily a product of interactions with other drugs, notably clobazam.
🧠 This elegant crossover trial challenges a common assumption in clinical practice by demonstrating that CBD’s seizure-reducing efficacy in approved indications may depend less on direct effects on neuronal excitability than on pharmacokinetic interactions with concurrent medications like clobazam, rather than intrinsic anticonvulsant properties. While the study’s rigorous design strengthens confidence in its negative findings regarding direct cortical effects, the relatively small sample size and focus on healthy volunteers or limited patient populations may not fully capture CBD’s effects in the complex neurobiological milieu of actual seizure disorders, particularly in polypharmacy scenarios. The lack of direct cortical suppression does not diminish CBD’s clinical utility in approved seizure indications, but rather refocuses our mechanistic understanding toward drug-drug interactions and potentially other downstream pathways. For practitioners prescribing CBD as adjunctive therapy, this finding underscores the importance of monitoring coadministered medications for altered metabolism and efficacy rather than attributing seizure control solely